Código QR

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

Guardado en:

Detalles Bibliográficos
Autores principales:	M Rizzo, I Colomer-Asenjo, G Cabello-Molina, S Marín-López, M Sutil-Vega, C Roca-Guerrero, F Taibi-Hajjami, D García-Vega, M Panelo-Rubio, M Bonastre-Thio, A Martínez-Rubio
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/13a7748dffbb483bbadb61a818cf6ee8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
por: M Rizzo, et al.
Publicado: (2020)

The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction
por: Osama A. Amin, et al.
Publicado: (2021)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Mauro Gori, et al.
Publicado: (2021)

Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction
por: Maria Vincenza Polito, et al.
Publicado: (2020)

Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Domingo Pascual-Figal, et al.
Publicado: (2021)

The effectiveness and tolerability of switching Indian patients from sacubitril/valsartan, ARNI to perindopril in heart failure with reduced ejection fraction. [Efficient study]
por: Pankaj Jariwala, et al.
Publicado: (2021)

Sacubitril/valsartan in real-life clinical practice
por: Yüksel Çavuşoğlu
Publicado: (2021)

Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats
por: Jiao Ai, et al.
Publicado: (2021)

Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hui-Ling Hsieh, et al.
Publicado: (2021)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
por: Cuthbert JJ, et al.
Publicado: (2020)

Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts
por: Xiaofei Li, et al.
Publicado: (2021)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
por: Oriol Iborra-Egea, et al.
Publicado: (2017)

Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
por: Hyoeun Kim, et al.
Publicado: (2021)

Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
por: Elodie Charuel, et al.
Publicado: (2021)

An Evaluation of the Initiation and Use of Sacubitril/Valsartan in an Inpatient Heart Failure Population: A Retrospective Medication Use Evaluation
por: Tara Snyder, et al.
Publicado: (2019)

Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
por: Ferhat Dindaş, et al.
Publicado: (2021)

Classification of heart failure: A farewell to ejection fraction?
por: Thomas F. Lüscher
Publicado: (2021)

Survival in Patients With Nonischemic Cardiomyopathy With Preserved vs Reduced Ejection Fraction
por: Nancy Luo, MD, MHS, et al.
Publicado: (2021)

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Veronika Zach, et al.
Publicado: (2020)

Role of nutritional supplementation in heart failure with reduced ejection fraction
por: Yash Paul Sharma, et al.
Publicado: (2021)

Efecto antihipertensivo del valsartán: Estudio multicéntrico nacional
por: Prat M.,Hernán
Publicado: (2000)

Plasma microrna expression profile for reduced ejection fraction in dilated cardiomyopathy
por: Maria Calderon-Dominguez, et al.
Publicado: (2021)

Visual versus fully automated assessment of left ventricular ejection fraction
por: Rami Mahmood Abazid, et al.
Publicado: (2018)

Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction
por: Ali Çoner, et al.
Publicado: (2021)

Determinants of gait speed in patients with heart failure with reduced ejection fraction
por: Aylin Tanrıverdi, et al.
Publicado: (2021)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
por: M. A. Manukyan, et al.
Publicado: (2021)

Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
por: Neal M Dixit, et al.
Publicado: (2021)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Hidekatsu Fukuta
Publicado: (2020)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Davide Margonato, et al.
Publicado: (2020)

Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction.
por: Jae Hyung Cho, et al.
Publicado: (2021)

Body Mass Index: An Effective Predictor of Ejection Fraction Improvement in Heart Failure
por: Li-fang Ye, et al.
Publicado: (2021)

A profile of heart failure with preserved ejection fraction in a teaching institute
por: Gaurav Aggarwal, et al.
Publicado: (2021)

Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype
por: Rebecca T. Levinson, et al.
Publicado: (2021)

Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
por: Sebastian Rosch, et al.
Publicado: (2020)

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?
por: Sebastiaan HC Klaassen, et al.
Publicado: (2020)

Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction
por: Pankaj Garg, et al.
Publicado: (2021)

Non-Invasive Assessment of Left Ventricle Ejection Fraction: Where Do We Stand?
por: Alessandra Scatteia, et al.
Publicado: (2021)

Magnetic Resonance Assessment of Ejection Fraction Versus Echocardiography for Cardioverter-Defibrillator Implantation Eligibility
por: Călin Schiau, et al.
Publicado: (2021)

Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis.
por: Feng Liu, et al.
Publicado: (2014)

Chamber-enriched gene expression profiles in failing human hearts with reduced ejection fraction
por: Xin Luo, et al.
Publicado: (2021)